Zasmidium cellare

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform

Retrieved on: 
Monday, November 6, 2023
Health, Infectious Diseases, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, CAR, Integrated development environment, Myositis, Science, technology, engineering, and mathematics, Cabaletta, Environment, Cell, Immune system, SDM, Partnership, TAP, Autoimmune disease, Scleroderma, GMP, Patient, Automation, Pharmaceutical industry, Vaccine, Science, Zasmidium cellare

Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.

Key Points: 
  • Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
  • Cellares’ innovative manufacturing technology transforms autologous and allogeneic cell therapy processes, covering nearly 90% of cell therapy modalities.
  • Through its TAP program, Cellares can facilitate the automation and tech transfer of manual processes onto the Cell Shuttle manufacturing platform in just six months.
  • With automation, standardization, and software-defined manufacturing (SDM), subsequent tech transfers become instant to any other Cell Shuttle in any IDMO Smart Factory worldwide.

Cellarity Announces Partnership with Chan Zuckerberg Initiative to Advance New Machine Learning Algorithms for Single-Cell Analysis

Retrieved on: 
Tuesday, October 17, 2023
Other Health, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Stem Cells, Other Science, Health, CZI, Algorithm, Partnership, Knowledge, Data science, NP-hardness, Biomedical Research, Machine learning, Biology, Single-cell analysis, Flagship Pioneering, Cell, Data, Chan Zuckerberg Initiative, Doctor of Philosophy, Benchmarking, Computational biology, Pharming, Drug discovery, Yale University, Patient, Mobile phone, Microscope, Kaggle, Zasmidium cellare

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, and the Chan Zuckerberg Initiative (CZI) today announced a partnership to drive innovation in machine learning (ML) algorithms for single-cell analysis via support of the Open Problems in Single-Cell Analysis initiative.

Key Points: 
  • Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, and the Chan Zuckerberg Initiative (CZI) today announced a partnership to drive innovation in machine learning (ML) algorithms for single-cell analysis via support of the Open Problems in Single-Cell Analysis initiative.
  • “Single-cell biology is at the forefront of biomedical research and data science.
  • Now more than ever, we recognize the importance of benchmarks and challenges to help bring data science and cutting-edge computational approaches to single-cell biology,” said Jonah Cool, Ph.D., Senior Program Officer of the Single-Cell Biology program at the Chan Zuckerberg Initiative.
  • The goal of this competition is to leverage advances in representation learning to unlock new capabilities bridging data science, machine learning, and computational biology.

Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Integrated development environment, Partnership, NYSE, Series, SDM, Automation, Bristol Myers Squibb, BMS, GMP, TAP, Growth, BMY, Fine chemical, Pharmaceutical industry, Zasmidium cellare

Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb (NYSE: BMY) will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership (TAP) program.

Key Points: 
  • Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb (NYSE: BMY) will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership (TAP) program.
  • As part of this expanded agreement, Cellares will optimize, automate, and tech-transfer the additional CAR-T cell therapy process onto its automated manufacturing platform, the Cell Shuttle.
  • Cellares’ TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company’s automated manufacturing technology for products in their pipeline.
  • Under the TAP program, manual processes can be automated and tech-transferred onto Cellares’ Cell Shuttle platform in only six months.

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

Retrieved on: 
Monday, September 11, 2023
GMP, Triple-negative breast cancer, TAP, Immunotherapy, Lung cancer, CAR, Patient, SAN, Cell, Integrated development environment, SDM, Automation, ROR1, Mobile phone, Vaccine, Lyell, Zasmidium cellare

Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.

Key Points: 
  • Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
  • As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell’s LYL797 CAR T-cell therapy, using the Cell Shuttle.
  • Cellares' innovative manufacturing technology transforms autologous and allogeneic cell therapy processes, covering nearly 90% of cell therapy modalities.
  • Through their TAP program, Cellares can facilitate the automation and tech transfer of manual processes onto the Cell Shuttle manufacturing platform in just six months.

Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform

Retrieved on: 
Monday, August 28, 2023
GMP, Zasmidium cellare, COGS, TAP, Bristol Myers Squibb, BMY, Integrated development environment, BMS, SDM, NYSE, Automation, Fine chemical, Pharmaceutical industry

Cellares' TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company's automated manufacturing technology for products in their pipeline.

Key Points: 
  • Cellares' TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company's automated manufacturing technology for products in their pipeline.
  • Bristol Myers Squibb is leveraging this program to evaluate the automated manufacturing process and produce comparability data confirming the Cell Shuttle as a viable, cost-efficient, and scalable manufacturing solution for cell therapies.
  • Cellares' flexible manufacturing technology supports both autologous and allogeneic cell therapy processes and approximately 90% of cell therapy modalities.
  • Manual processes can be automated and tech-transferred onto Cellares' automated Cell Shuttle platform in only six months via the company's Technology Adoption Partnership (TAP) program.

Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform

Retrieved on: 
Monday, August 28, 2023
GMP, Zasmidium cellare, COGS, TAP, Bristol Myers Squibb, BMY, Integrated development environment, BMS, SDM, NYSE, Automation, Fine chemical, Pharmaceutical industry

Cellares' TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company's automated manufacturing technology for products in their pipeline.

Key Points: 
  • Cellares' TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company's automated manufacturing technology for products in their pipeline.
  • Bristol Myers Squibb is leveraging this program to evaluate the automated manufacturing process and produce comparability data confirming the Cell Shuttle as a viable, cost-efficient, and scalable manufacturing solution for cell therapies.
  • Cellares' flexible manufacturing technology supports both autologous and allogeneic cell therapy processes and approximately 90% of cell therapy modalities.
  • Manual processes can be automated and tech-transferred onto Cellares' automated Cell Shuttle platform in only six months via the company's Technology Adoption Partnership (TAP) program.

Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

Retrieved on: 
Tuesday, June 6, 2023
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Cloud, Interim, Therapy, Pharming, Medical imaging, Radiology, Biomedical Research, Geisinger Health System, Microsoft, Global health, Health informatics, Wayne State University School of Medicine, Stanford University School of Medicine, Acquisition, Flagship Pioneering, Patient, Machine learning, Engineering, Neuroradiology, Informatics, Corporation, Biology, AI, Ecosystem, NYSE, Disease, Penn State University College of Medicine, Medical device, Zasmidium cellare, Nuance

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company’s Board of Directors.

Key Points: 
  • Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company’s Board of Directors.
  • “Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation,” said Stephen Berenson, Chairman of Cellarity’s Board of Directors and Managing Partner at Flagship Pioneering.
  • Dr. Moore is board certified in Diagnostic Radiology, Neuroradiology, and Clinical Informatics.
  • He currently serves as an independent director on the boards of DaVita (NYSE:DVA) and Olink Holding AB (NASDAQ:OLK).

Cellares Hires Former Novartis Executive and Bristol-Myers Squibb Alum to Lead Commercialization

Retrieved on: 
Wednesday, April 12, 2023
Marketing research, Commercialization, EVP, Innovation system, Business, Bristol Myers Squibb, Associate, Marketing, Novartis, Patient, SAN, Research, FDA, Therapy, Pharmaceutical industry, Fine chemical, Tisagenlecleucel, Zasmidium cellare

Prior to this, Araya served as Vice President for Global Commercial Strategy for several multi-billion dollar Novartis Oncology products.

Key Points: 
  • Prior to this, Araya served as Vice President for Global Commercial Strategy for several multi-billion dollar Novartis Oncology products.
  • More recently, he served as the EVP and Chief Commercial Officer at Brainstorm Cell Therapeutics, where he prepared for the commercialization of the company's lead cell therapy product to treat neurodegenerative diseases.
  • Araya also has experience working with biopharma giant Bristol-Myers Squibb, where he served as Associate Director of Marketing Research and Business.
  • In his new role at Cellares, Araya will lead commercialization efforts for the company's Cell Shuttle, an enclosed, end-to-end, fully automated solution for scaling cell therapy manufacturing.

Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Retrieved on: 
Wednesday, August 17, 2022
Research, Technology, Genetics, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Rubius, Machine learning, Hematology, Single-cell analysis, CEO, Algorithm, Ecosystem, Growth, B cell, Investment, CD34, Disease, Differentiable function, Flagship, David Berry (inventor), Tissue, Knowledge, Method, Life, Blood, Lists of diseases, MRNA, NP-hardness, DNA, Cell, Bone marrow, Data, Conference on Neural Information Processing Systems, RNA, NASDAQ, Biology, Doctor of Pharmacy, Respiratory disease, HSPC, Protein, SANA, Yale University, Flagship Pioneering, Time, Health, Adult, Mobile phone, Vaccine, Medical imaging, Kaggle, Zasmidium cellare

This time course will be used to power a competition to develop algorithms that learn the underlying relationships between DNA, RNA, and protein modalities across time.

Key Points: 
  • This time course will be used to power a competition to develop algorithms that learn the underlying relationships between DNA, RNA, and protein modalities across time.
  • Solving this open problem will help elucidate complex regulatory processes that are the foundation for cell differentiation in health and disease.
  • New machine learning algorithms are needed to learn the rules that govern complex cell regulatory processes so we can predict how cell state changes over time.
  • This translation of knowledge across disciplines is expected to drive more powerful algorithms to learn fundamental rules of biology.